9.72
-0.84(-7.95%)
Currency In USD
| Previous Close | 10.56 |
| Open | 12.5 |
| Day High | 13.26 |
| Day Low | 7.45 |
| 52-Week High | 18.35 |
| 52-Week Low | 5 |
| Volume | 1.09M |
| Average Volume | 46,139 |
| Market Cap | 12.26M |
| PE | -0.51 |
| EPS | -19.14 |
| Moving Average 50 Days | 9.9 |
| Moving Average 200 Days | 8.43 |
| Change | -0.84 |
If you invested $1000 in Sensei Biotherapeutics, Inc. (SNSE) since IPO date, it would be worth $25.71 as of December 06, 2025 at a share price of $9.72. Whereas If you bought $1000 worth of Sensei Biotherapeutics, Inc. (SNSE) shares 3 years ago, it would be worth $337.5 as of December 06, 2025 at a share price of $9.72.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results
GlobeNewswire Inc.
Nov 14, 2025 12:30 PM GMT
BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial res
Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value
GlobeNewswire Inc.
Oct 30, 2025 1:00 PM GMT
BOSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that its Boa
Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025
GlobeNewswire Inc.
Oct 17, 2025 12:00 PM GMT
6-month progression-free survival (PFS) of 50% in the higher 15 mg/kg dose cohort compares favorably to historical PD-(L)1 refractory settings –All clinical responses, including a complete response, observed in the higher 15 mg/kg dose cohort –Favora